Adverum Biotechnologies (STU:AVU0) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies 3-Year Revenue Growth Rate?

Adverum Biotechnologies's Revenue per Share for the three months ended in Mar. 2024 was €0.00.

During the past 12 months, Adverum Biotechnologies's average Revenue per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Adverum Biotechnologies was 42.70% per year. The lowest was -54.00% per year. And the median was -19.35% per year.

Competitive Comparison of Adverum Biotechnologies's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Adverum Biotechnologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's 3-Year Revenue Growth Rate falls into.

Adverum Biotechnologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Adverum Biotechnologies (STU:AVU0) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Adverum Biotechnologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (STU:AVU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines